The second conclusion is to modify existing anticancer therapies to include GLP-1 agonists, DPP-4i, or SGLT2i, especially in a patient with coexisting diabetes or obesity. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.